title: Targeted therapy in gastrointestinal malignancies.
abstract: Increased understanding of cancer pathogenesis has identified several pathways that serve as potential targets for novel targeted agents in development. The selection of targeted cancer therapy based on biomarkers has instigated a new era of personalized medicine and changed the way we practice oncology. Many targeted agents are approved for treatment of gastrointestinal malignancies most targeting tumor angiogenesis, and many more are in different phases of development. Here we briefly summarize nine different targeted agents that are approved currently in the U.S. and several other agents currently being studied in various gastrointestinal cancers.
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Chhatrala
authors.affiliation: Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Thanavala
authors.affiliation: Department of Medicine, Division of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Renuka
authors.initials: R
authors.lastname: Iyer
keywords: Gastrointestinal cancers; monoclonal antibodies; targeted drugs; tyrosine kinase inhibitors
references.citation: Clin Colorectal Cancer. 2013 Sep;12(3):145-51
references.pmid: 23763824
references.citation: J Clin Oncol. 2013 Apr 1;31(10):1341-7
references.pmid: 23358972
references.citation: Neoplasia. 2013 Feb;15(2):143-55
references.pmid: 23441129
references.citation: Cancer Chemother Pharmacol. 2011 Jul;68(1):255-62
references.pmid: 21526353
references.citation: J Clin Oncol. 2012 Oct 10;30(29):3596-603
references.pmid: 22965965
references.citation: Biomed Pharmacother. 2012 Feb;66(1):12-20
references.pmid: 22265104
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1904-10
references.pmid: 20231677
references.citation: Int J Cancer. 2010 Sep 1;127(5):1197-208
references.pmid: 20039326
references.citation: Lancet. 2010 Aug 28;376(9742):687-97
references.pmid: 20728210
references.citation: J Clin Oncol. 2013 Oct 1;31(28):3509-16
references.pmid: 23980090
references.citation: Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
references.pmid: 15451219
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Mol Cancer Ther. 2011 Jun;10(6):1007-17
references.pmid: 21487053
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4706-13
references.pmid: 20921462
references.citation: Lancet Oncol. 2009 Jun;10(6):559-68
references.pmid: 19482548
references.citation: Ann Oncol. 2007 Jul;18(7):1185-9
references.pmid: 17483115
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3605-10
references.pmid: 20606093
references.citation: Eur J Cancer. 2006 May;42(8):1093-103
references.pmid: 16624552
references.citation: Ann Oncol. 2012 Jul;23(7):1680-7
references.pmid: 22357255
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):7074-9
references.pmid: 18981005
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4922-7
references.pmid: 17050876
references.citation: J Clin Oncol. 2011 Jun 10;29(17):2357-63
references.pmid: 21519026
references.citation: Mol Cancer Ther. 2013 Oct;12(10):2121-34
references.pmid: 23960095
references.citation: N Engl J Med. 2011 Feb 10;364(6):514-23
references.pmid: 21306238
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references.pmid: 18316791
references.citation: Clin Adv Hematol Oncol. 2012 Jul;10(7):430-7
references.pmid: 22895283
references.citation: Br J Cancer. 2012 Mar 13;106(6):1033-8
references.pmid: 22374460
references.citation: Curr Med Res Opin. 2007 Sep;23(9):2117-23
references.pmid: 17651538
references.citation: Invest New Drugs. 2011 Oct;29(5):1021-8
references.pmid: 20127139
references.citation: J Clin Oncol. 2007 May 20;25(15):1960-6
references.pmid: 17452677
references.citation: Am J Clin Oncol. 2012 Aug;35(4):329-33
references.pmid: 21422991
references.citation: Cancer Res. 2002 Jul 15;62(14):4132-41
references.pmid: 12124352
references.citation: J Clin Oncol. 2013 Oct 1;31(28):3517-24
references.pmid: 23980084
references.citation: Lancet. 2013 Jan 26;381(9863):303-12
references.pmid: 23177514
references.citation: Lancet Oncol. 2010 Oct;11(10):942-9
references.pmid: 20864406
references.citation: Anat Rec (Hoboken). 2012 Dec;295(12):2122-8
references.pmid: 22907845
references.citation: Clin Cancer Res. 2013 Jul 15;19(14):3987-95
references.pmid: 23743569
references.citation: Ann Oncol. 2013 Sep;24(9):2335-41
references.pmid: 23788755
references.citation: Cancer. 2012 Nov 15;118(22):5497-506
references.pmid: 22569804
references.citation: Int J Clin Oncol. 2014 Apr;19(2):297-302
references.pmid: 23690261
references.citation: Cancer. 2011 Nov 15;117(22):5094-102
references.pmid: 21538343
references.citation: Ann Oncol. 2013 Jun;24(6):1580-7
references.pmid: 23463625
references.citation: Clin Cancer Res. 2012 Feb 15;18(4):1051-62
references.pmid: 22173548
references.citation: Cancer. 2008 Jun 15;112(12):2733-9
references.pmid: 18412149
references.citation: J Clin Oncol. 2009 Feb 10;27(5):672-80
references.pmid: 19114685
references.citation: J Hepatol. 2004 Dec;41(6):1008-16
references.pmid: 15582135
references.citation: Oncology. 2013;85(1):53-8
references.pmid: 23860007
references.citation: Ai Zheng. 2007 Dec;26(12):1330-5
references.pmid: 18076795
references.citation: Invest New Drugs. 2012 Jun;30(3):1216-23
references.pmid: 21594619
references.citation: J Clin Oncol. 2011 May 20;29(15):2004-10
references.pmid: 21464401
references.citation: Clin Cancer Res. 2005 Sep 15;11(18):6650-6
references.pmid: 16166444
references.citation: Cancer. 2013 Jan 15;119(2):380-7
references.pmid: 22833179
references.citation: Br J Cancer. 2012 Sep 25;107(7):1044-50
references.pmid: 22910317
references.citation: Eur J Cancer. 2013 Aug;49(12):2633-42
references.pmid: 23642329
references.citation: Ann Oncol. 2012 Apr;23(4):933-41
references.pmid: 21828378
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7480-9
references.pmid: 16243822
references.citation: Oncol Rep. 2010 Apr;23(4):1167-72
references.pmid: 20204306
references.citation: Pathology. 2012 Oct;44(6):547-51
references.pmid: 22935976
references.citation: World J Gastroenterol. 2005 Mar 7;11(9):1382-6
references.pmid: 15761981
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3141-7
references.pmid: 19451435
references.citation: J Clin Oncol. 2011 May 20;29(15):1997-2003
references.pmid: 21464406
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5613-9
references.pmid: 16110021
references.citation: J Clin Oncol. 2011 Jan 1;29(1):11-6
references.pmid: 20940184
references.citation: N Engl J Med. 2009 Apr 2;360(14):1408-17
references.pmid: 19339720
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3499-506
references.pmid: 22949147
references.citation: J Radiat Res. 2013 Jan;54(1):52-60
references.pmid: 22923745
references.citation: Cancer Invest. 2008 Oct;26(8):784-93
references.pmid: 18798073
references.citation: Lancet Oncol. 2012 Feb;13(2):181-8
references.pmid: 22192731
references.citation: Eur J Cancer. 2013 Nov;49(17):3609-15
references.pmid: 23899530
references.citation: Cancer Sci. 2013 Jun;104(6):687-93
references.pmid: 23438367
references.citation: J Clin Oncol. 2010 Jun 20;28(18):2947-51
references.pmid: 20458043
references.citation: Invest New Drugs. 2012 Jun;30(3):1138-43
references.pmid: 21170759
references.citation: Lancet. 2013 Jan 26;381(9863):295-302
references.pmid: 23177515
references.citation: Target Oncol. 2013 Jun;8(2):127-36
references.pmid: 23625191
references.citation: Ann Oncol. 2013 Jul;24(7):1777-1785
references.pmid: 23510984
references.citation: Ann Oncol. 2012 Nov;23(11):2834-2842
references.pmid: 22700995
references.citation: Tumori. 2013 Mar-Apr;99(2):176-82
references.pmid: 23748811
references.citation: J Clin Oncol. 2012 Oct 10;30(29):3588-95
references.pmid: 22965961
references.citation: J Clin Oncol. 2008 Feb 1;26(4):626-32
references.pmid: 18235122
references.citation: Ann Oncol. 2012 Nov;23(11):2799-2805
references.pmid: 22771827
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2786-94
references.pmid: 20810605
references.citation: Cancer. 2011 Apr 1;117(7):1409-14
references.pmid: 21425140
references.citation: Oncologist. 2013;18(3):271-2
references.pmid: 23485624
references.citation: Am J Clin Oncol. 2013 Jun;36(3):254-7
references.pmid: 22643560
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5201-6
references.pmid: 17114652
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4697-705
references.pmid: 20921465
references.citation: Eur J Cancer. 2013 Nov;49(16):3412-9
references.pmid: 23809766
references.citation: J Clin Oncol. 2013 Jul 1;31(19):2477-84
references.pmid: 23690424
references.citation: Lancet Oncol. 2013 Jul;14(8):749-59
references.pmid: 23725851
references.citation: Clin Cancer Res. 2012 Jun 1;18(11):3170-9
references.pmid: 22661587
references.citation: PLoS One. 2012;7(12):e49717
references.pmid: 23284624
references.citation: Mol Cancer Ther. 2009 Sep;8(9):2546-58
references.pmid: 19755510
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4793-9
references.pmid: 17947727
references.citation: Endocr Relat Cancer. 2013 May 21;20(3):383-90
references.pmid: 23572164